S9630, Medroxyprogesterone in Treating Women With Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00002920
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : October 31, 2012
National Cancer Institute (NCI)
Cancer and Leukemia Group B
Information provided by (Responsible Party):
Southwest Oncology Group

November 1, 1999
January 27, 2003
October 31, 2012
March 1997
December 2006   (Final data collection date for primary outcome measure)
Endometrial pathologic diagnosis [ Time Frame: 2 years after registration ]
Endometrial pathologic diagnosis at 2 years after registration
Not Provided
Complete list of historical versions of study NCT00002920 on Archive Site
Endometrial pathologic diagnosis [ Time Frame: 5 years after registration ]
Endometrial pathologic diagnosis at 5 years after registration
Not Provided
Not Provided
Not Provided
S9630, Medroxyprogesterone in Treating Women With Breast Cancer
A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With Tamoxifen, Phase III

RATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing endometrial disorder in patients with breast cancer who are taking tamoxifen.

PURPOSE: Randomized phase III trial to study the effectiveness of medroxyprogesterone in preventing endometrial disorder in postmenopausal women who have ductal carcinoma in situ, lobular carcinoma in situ, Paget's disease of the nipple, stage I breast cancer, or stage II breast cancer and who are taking tamoxifen.


  • Compare endometrial pathologic diagnoses (proliferative changes, simple or cystic hyperplasia, complex adenomatous hyperplasia, hyperplasia with atypia, and carcinoma) in postmenopausal women with breast carcinoma treated with adjuvant tamoxifen who are randomly assigned to medroxyprogesterone acetate (MA) vs observation.
  • Compare endometrial pathologic diagnoses (persistent endometrial hyperplasia, atypia, or carcinoma) resulting in tamoxifen discontinuation and intermittent bleeding in patients treated with these regimens.
  • Characterize the incidence of spontaneous regression and progression of simple or cystic hyperplasia in these patients.
  • Characterize endometrial biopsy results using different endometrial stripe width cut-off points, for cases in which the width is at least 5 mm by endovaginal ultrasound in patients receiving tamoxifen.
  • Compare changes over time in endometrial oncogene expression (e.g., c-fos, c-jun, p53, IGF1) and receptor status in patients receiving tamoxifen with or without prior chemotherapy who are randomly assigned to MA vs observation.
  • Describe the associations among change in gene expression, receptor status, endometrial abnormality, length of tamoxifen exposure, and prior chemotherapy in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to adjuvant chemotherapy (yes vs no), number of positive nodes (0-3 vs at least 4), and endovaginal sonogram endometrial stripe (less than 5 mm vs at least 5 mm). Patients are randomized to 1 of 2 arms.

All patients receive adjuvant oral tamoxifen daily for five years.

  • Arm I: Patients undergo observation.
  • Arm II: Patients receive oral medroxyprogesterone acetate on days 1-14. Treatment repeats every 3 months for 5 years.

Patients are followed every 6 months for 2 years and then annually thereafter.

PROJECTED ACCRUAL: A total of 330 patients (165 per arm) will be accrued for this study.

Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
  • Breast Cancer
  • Endometrial Cancer
  • Drug: medroxyprogesterone
  • Drug: tamoxifen citrate
  • Procedure: adjuvant therapy
  • Active Comparator: Tamoxifen alone
    Tamoxifen alone x 5 years
    • Drug: tamoxifen citrate
    • Procedure: adjuvant therapy
  • Experimental: Tamoxifen plus MPA
    Tamoxifen Plus Medroxyprogesterone Acetate (MPA) x 5 years
    • Drug: medroxyprogesterone
    • Drug: tamoxifen citrate
    • Procedure: adjuvant therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
December 2009
December 2006   (Final data collection date for primary outcome measure)


  • One of the following histologically proven diagnoses:

    • Primary invasive adenocarcinoma of the unilateral or bilateral breast

      • Stage I, IIA, or IIB (T1-3, N0-1, M0)
      • No recurrent invasive breast cancer
    • Ductal carcinoma in situ (DCIS)
    • Lobular carcinoma in situ (LCIS) with microinvasion
    • Paget's disease of the nipple
  • No sarcoma, lymphoma, or apocrine, adenocystic, or squamous cell cancer of the breast
  • Currently free of breast cancer (no evidence of disease)

    • No evidence of distant disease on chest x-ray or chest CT scan and mammogram of the opposite breast within the past year
  • Prior definitive local treatment of primary lesion (mastectomy or breast-sparing procedure with radiotherapy) and either axillary node or sentinel node biopsy

    • Surgical margins clear of both infiltrating carcinoma (any type) and DCIS

      • No gross or microscopically positive margins except:

        • Invasive cancer or DCIS at the focal margin treated with definitive radiotherapy
        • Gross or LCIS at the final margin
    • Biopsy requirement waived for DCIS or LCIS with minimal microinvasion
  • Patients with breast-sparing procedure must have received or be planning to receive radiotherapy at start of tamoxifen treatment
  • No endometrial simple or cystic hyperplasia, proliferative changes, complex (adenomatous) or atypical hyperplasia, or carcinoma
  • Patients must be planning one of the following:

    • Starting adjuvant tamoxifen for five years OR
    • Started tamoxifen within 28 days prior to study and planning to receive adjuvant tamoxifen for five years
  • Hormone receptor status:

    • Candidate for adjuvant tamoxifen therapy



  • Adult


  • Female

Menopausal status:

  • Postmenopausal defined as:

    • At least 1 year since last menstrual period
    • At least 2 months since bilateral oophorectomy prior to breast cancer diagnosis
    • 4-12 months since last menstrual period and FSH elevated to postmenopausal range
    • Postmenopausal estrogen therapy and 55 years of age or older

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • Fertile patients must use effective contraception during and for at least 2 months after study
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer currently in complete remission
  • No concurrent nonmalignant-related illness that would preclude study


Biologic therapy:

  • Not specified


  • Adjuvant chemotherapy allowed
  • No concurrent chemotherapy

Endocrine therapy:

  • See Disease Characteristics
  • No prior hormonal treatment for breast cancer (except tamoxifen)
  • No concurrent postmenopausal estrogen therapy


  • See Disease Characteristics


  • See Disease Characteristics
  • No prior or concurrent hysterectomy


  • No prior or current participation in an adjuvant intergroup trial
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
CALGB-49901 ( Other Identifier: CALGB )
S9630 ( Other Identifier: SWOG )
U10CA037429 ( U.S. NIH Grant/Contract )
U10CA032102 ( U.S. NIH Grant/Contract )
Not Provided
Not Provided
Southwest Oncology Group
Southwest Oncology Group
  • National Cancer Institute (NCI)
  • Cancer and Leukemia Group B
Study Chair: Ronald K. Potkul, MD Loyola University
Study Chair: Barbara L. Smith, MD, PhD Massachusetts General Hospital
Southwest Oncology Group
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP